Anti-FLIPγ/δ, C-Terminal antibody produced in rabbit

MFCD02096351

NA.41

In human Viral FLICE-inhibitory proteins (v-FLIPs) is identified as c-FLIP. It is composed of two death effector domains which have structural resemblance with the N-terminal half of caspase-8 and a caspase-like domain. It exist as multiple splice variants: FLIP α, β, γ and δ. Along with splice variants, it has two endogenous forms of the protein − c-FLIP_long and c-FLIP_short.

FLIP antibody was raised against a 19 amino acid peptide near the carboxy terminus of human FLIP.
The immunogen is located within amino acids 180 - 230 of FLIP.

Anti-FLIPγ/δ, C-Terminal antibody is suitable for microarray and western blot at a dilution of 1:1,000 using HeLa, Jurkat, THP-1, A431, K562, and NIH-3T3 cell lysates.

C-FLIP plays an important role in apoptosis signaling pathways. It acts as proapoptotic molecule or as an anti-apoptotic molecule. It has been reported that c-FLIP can interact with both FADD and caspase-8. It prevents caspase-8 recruitment and processing through DED-DED (Death Effector Domain) interaction followed by CD95-induced apoptosis.

Solution in 0.01 M phosphate buffered saline containing 0.02% sodium azide.

rabbit

200

unconjugated

affinity isolated antibody

primary antibodies

polyclonal

buffered aqueous solution

antigen 25 kDa (FLIPδ/FLIP_S)
antigen 35 kDa (FLIPγ)

human, mouse

1 mg/mL

immunocytochemistry: 2 μg/mL
immunofluorescence: 10 μg/mL
western blot: 1:1,000

O15519

−20℃

human ... CFLAR(8837)
mouse ... Cflar(12633)

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.